Back

Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure

European Heart Journal

15 February 2016
Organised by: Logo
Read full article
ESC Journals

Contributors

Eugene Braunwald
Eugene Braunwald

Author

Brigham and Women's Hospital, Harvard Medical School Boston , United States of America

You may be interested in
thumbnail
ESC Journals
Impact of angiotensin-receptor neprilysin inhibitor on reverse cardiac remodeling in patients with heart failure with reduced ejection fraction (hfref)
4 February 2022
thumbnail
Congress Session
What’s on the horizon in heart failure: precision medicine and tailored treatment
18 May 2025
thumbnail
Congress Presentation
Neprilysin as a heart failure biomarker: addressing challenges and exploring new directions
19 May 2025
thumbnail
Congress Presentation
Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure
30 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources